Benzinga

Benzinga

Benzinga

viernes, agosto 21

Bright Minds Biosciences Inc

DRUGNASDAQ
Trade with Public
Trade with Public
$78.56
-6.18-7.29%
al cierre: Aug 20, 5:00 PM EST
$84.01
5.456.94%
After hour: Aug 19, 9:23 AM EST
Ganancias: Los beneficios de Q3 2026 se publicaron el lun ago 17th, antes de la apertura del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Bright Minds Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bright Minds Biosciences (DRUG).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$128Upside to Avg. PT+52.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$145
Aug 17, 2026BTIGThomas ShraderMaintainedBuy$147
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.
Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved